Myelodysplastic syndromes are a group of small-incidence malignancies that represent a significant challenge to many community oncologists. In this activity, participants will hear from two key experts about a variety of topics including, but not limited to: personalized risk stratification, iron overload, immunotherapies, and new strategies for treating lower- and higher-risk MDS. Join Dr. Sekeres and Dr. Steensma as they discuss incorporating molecular abnormalities into diagnosis and prognosis, and where luspatercept and imetelstat may fit into the future of MDS treatment. Learn More and Begin Course
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
Dr. Goldberg discusses when it is appropriate to stop a patient’s demethylating agent, taking into consideration age and IPSS-R risk group. Learn More and Watch the Video
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
Nurses Workshop – The Nurse and the MDS Patient Management
Opening Ceremony & Keynote Lecture
PS 1 – Dysimmunity, Inflammation and MDS
PS 2 – From Clonal Hematopoiesis to Overt MDS
PS 3 – Prognostication and Stratification of MDS
PS 4 – Dyserythropoiesis in MDS
PS 5 – Predisposition to MDS
PS 6 – Druggable mutations and other personalized approaches for the treatment of MDS
PS 7 – Non Targeted Approaches for HR MDS
PS 8 – Outcome Researches
PS 9 – CMML and Other Specific Sub Types of MDS and MDS/MPN
PS 10 – Innovations in Transplantation and Cellular Immunotherapy for MDS Patients
Keynote Lecture
Tito Bastianello & MDSF Young Investigators Awards & Presentations
Opening Ceremony
Classification, Prognostication Session
WHO 2022 & ICC, others Lecture
VEXAS Syndrome Lecture
Clonal Hematopoiesis/Inflammation Session
Response Criteria Lecture
Clinical / Lower Risk MDS-1 Session
Clinical / Lower Risk MDS-2/Tx Session
Morphology Lecture
Future Diagnostics Session
Germline Predisposition Session
Case Discussion
Clinical/Higher Risk MDS Session
MDS/MPN Session
Closing Ceremony
